The involvement of the *DLX3* gene in isolated or syndromic amelogenesis imperfecta



Orodental diseases Autoimmune diseases Maladies bucco-dentaires Maladies auto-immunes Autoimmunerkrankungen Erkrankungen im Mund- und Zahnbereich

Gaétan Caravello^{1,2}, Marzena Kawczynski², Tristan Rey^{1,2,3}, Isaac Maximiliano Bugueno^{2,3,4}, Virginie Laugel-Haushalter^{1,3,4}, Manuela Antin¹, Serena Lopez⁵, Jean-Jacques Morrier⁶, Laeticia Dallmann-Raidot⁷, Bénédicte Gérard¹, Aurélie Gouronc¹, Caroline Schluth-Bolard¹, Agnès Bloch-Zupan^{2,3,4}

¹Hôpitaux Universitaires de Strasbourg (HUS), Laboratoire de diagnostic génétique, Institut de Génétique, Institut de Génétique, Institut de Génétique Médicale d'Alsace, Strasbourg, France ; ²HUS, Pôle de médecine et chirurgie bucco-dentaires, Centre de référence des maladies rares orales et dentaires, CRMR O-Rares, Strasbourg, Filière TETECOU - ERN CRANIO ; ³Université de Strasbourg, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), UNISTRA UMR7104, INSERM U1258, Illkirch-Graffenstaden, France ; ⁴Université de Strasbourg, Faculté de Chirurgie Dentaire ; ⁵Centre de compétence des maladies rares orales et dentaires, CCMR, Nantes, France ; ⁶Centre Hospitalier Universitaire de Lyon, Centre de compétence des maladies rares orales et dentaires, CCMR, Lyon, France ; ⁷GHR Mulhouse Sud Alsace, Mulhouse, France

Introduction

Amelogenesis imperfecta (AI) is a heterogeneous set of rare genetic diseases The DLX3 gene (17q21.33, three exons) encodes a transcription factor affecting enamel development. Clinical phenotypes of enamel can be described in osteogenic differentiation, and more specifically in the development of the forebrain and craniofacial mass. as:

- **1.** Hypoplastic: quantitative defect of the enamel, thinner, pitted or striated, up to agenesis of the enamel
- **2.** Hypomineralized: sub-mineralization making the enamel softer, rougher, and more colorful **3.** Hypomature: relatively hard enamel but not translucent or even coloured AI can be **isolated** or **syndromic**. Currently, more than 100 causative genes have been identified, including the *DLX3* gene. It is involved in two distinct entities of autosomal dominant inheritance: > Hypomature AI with non-syndromic taurodontism known as type IV (OMIM # 104510) > Trichodento-bone syndrome (TDO) (OMIM #190320), a form of ectodermal dysplasia with curly hair and bone abnormalities

gaetan.caravello@chru-strasbourg.fr agnes.bloch-zupan@unistra.fr

Contact

<u>Figure 1 : Photos and X-rays depicting the different types of AI</u> From left to right: **hypoplastic**, **hypomineralized**, **hypomature**

Results

1. The NGS panel GenoDENT in the context of rare oral and dental diseases (Figure 2)

Individuals with AI can benefit from specific care in the O-Rares network including molecular diagnosis:

\rightarrow NGS panel GenoDENT (Prasad *et al.*, 2016; Rey *et al.*, 2019) **v7 = 676 genes** \rightarrow Exome sequencing

2. Novel mutations identified in *DLX3*

We identified **five variations** (Figure 3 & Table 1), three of which were in 3 families with an isolated hypoplastic AI phenotype and two in 2 families with a syndromic AI phenotype. Clinically, the enamel is hypoplastic, thin with sometimes the presence of wells; the molars have a root morphological abnormality seen on



Oragene•DNA Kit (OG-600) **DNA Genotek**



called radiographs taurodontism (Figure 3).

<u>Figure 3: Photos and X-rays of patients with DLX3-related AI</u> Isolated AI (mutation c.537C>A, left) or syndromic AI (mutation c.561_562del, right)



Exons are shown in **dark blue**, introns in **yellow**, and UTRs in **light blue**. Major protein domains are shown below the gene, in **green**. The identified

mutations are located in exons 1 and 3.

Conclusion

The use of diagnostic tools in molecular biology such as sequencing on a panel of genes and the exome has made it possible to identify new genetic variants involved in these hypoplastic AIs linked to *DLX3* and thus to **improve patient management**. AI with taurodontism and TDO could be two allelic diseases. Finally, if variants of unknown significance (VSI) are identified, they could be studied in **cell and/or organoid culture research** with a view to determining their impact and possibly reclassifying them as probably pathogenic (class 4) or pathogenic (class 5).

Acknowledgements

We would like to thank the patients, Dr. Pascal KEDINGER, Dr. 🦯 Alinoë LAVILLAUREIX, Dr. Béatrice THIVICHON-PRINCE and Grand Est Dr. Emmanuelle GINGLINGER for their contribution to this study.

This work is supported by E-GENODENT, Regional Intervention Fund of the Grand Est Regional Health Agency Health Innovation (2022-2025); the EU ERDF Interreg V Upper Rhine RARENET; the HEAD & NECK Sector.













